NCT07767448
Skin Changes From the Use of Moisturizers in Participants With Cancer Experiencing Dermatological Adverse Events
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 10 words Show 4 more changesShow less
- Start date pushed from Oct 2026 to Nov 2026
- Interventions modified
- Secondary endpoints: details revised at 3 of 3 entries
- Collaborators: details revised at 1 of 1 entry
- Notable Start date: Aug 2026 to Oct 2026
- Study title shortened, about 2 words
- Minor Study title shortened, about 4 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (3)
Arms and interventions
Participants in this arm will apply the following cosmeceutical topical moisturizers twice daily (once in the morning and once in the evening) for the duration of the study: 1. CeraVe Moisturizing Cream (once in the morning and once in the evening) 2. La Roche Posay Lipikar AP+ triple repair moisturizing cream (once in the morning and once in the evening) 3. La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+) (once in the morning and once in the evening)
Other: CeraVe Moisturizing Cream, La Roche Posay Lipikar AP+ Triple Repair Moisturizing Cream, La Roche Posay Cicaplast balm Panthenol/Vitamin B5 (B5+)
Sites
1 site in 1 country
- Stanford Health Care: Supportive Dermato-Oncology ProgramPalo Alto, California, United States